Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.

Trial Profile

Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACHIEVE-2/3
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 03 Jul 2012 Planned number of patients changed from 920 to 928 as reported by European Clinical Trials Database.
    • 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
    • 02 Jul 2010 Results were published in Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top